文献速递肝病

肝硬化合并SARS-CoV-2感染患者病死率下降:国家COVID队列协作研究

Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-23

该研究利用国家COVID队列协作(N3C)数据,纳入2020年3月至2023年11月117,811例感染SARS-CoV-2的慢性肝病(CLD)患者,其中肝硬化27,428例、无肝硬化90,383例。观察到30天病死率(CFR)在整个研究期间分别为无肝硬化1.1%、肝硬化6.3%,且自2022年起呈持续下降趋势。与2020年第二季度感染相比,2023年第三季度感染调整后30天死亡风险在无肝硬化患者为0.20(95%CI 0.08-0.50),肝硬化患者为0.35(95%CI 0.18-0.69)。

要点

  • 肝硬化合并SARS-CoV-2感染患者30天病死率在整个研究期间为6.3%,无肝硬化患者为1.1%。
  • 自2022年起,两类患者 observed 30天病死率均呈持续下降趋势。
  • 2023年第三季度感染较2020年第二季度,肝硬化患者调整后30天死亡风险为0.35(95%CI 0.18-0.69)。

核心结论

  • 在N3C研究中,合并或不合并肝硬化的慢性肝病患者 observed 30天病死率均逐步下降,与普通人群的总体趋势一致。

研究设计与样本

  • 利用N3C level 3数据集(含未删失日期),识别截至2023年11月所有感染SARS-CoV-2的慢性肝病患者(伴或不伴肝硬化),按感染月份描述 observed 30天病死率,并采用调整生存分析计算感染月份与2020年第二季度(疫情初期)感染相比的相对死亡风险。
  • 共纳入2020年3月至2023年11月间117,811例感染SARS-CoV-2的慢性肝病患者,其中肝硬化27,428例(23%),无肝硬化90,383例(77%)。

主要发现

  • 整个研究期间 observed 30天病死率:无肝硬化慢性肝病患者为1.1%(1016例),肝硬化患者为6.3%(1732例)。
  • 按感染月份统计的 observed 30天病死率在整个疫情期间有波动,自2022年起呈持续下降趋势。
  • 与2020年第二季度感染相比,2023年第三季度感染调整后30天死亡风险:无肝硬化慢性肝病患者为0.20(95%CI 0.08-0.50),肝硬化患者为0.35(95%CI 0.18-0.69)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The virulence and severity of SARS-CoV-2 infections have decreased over time in the general population due to vaccinations and improved antiviral treatments. Whether a similar trend has occurred in patients with cirrhosis is unclear. We used the National COVID Cohort Collaborative (N3C) to describe the outcomes over time. METHODS: We utilized the N3C level 3 data set with uncensored dates to identify all patients with chronic liver disease (CLD) with and without cirrhosis who had SARS-CoV-2 infection as of November 2023. We described the observed 30-day case fatality rate (CFR) by month of infection. We used adjusted survival analyses to calculate relative hazard of death by month of infection compared with infection at the onset of the COVID-19 pandemic. RESULTS: We identified 117,811 total patients with CLD infected with SARS-CoV-2 between March 2020 and November 2023: 27,428 (23%) with cirrhosis and 90,383 (77%) without cirrhosis. The observed 30-day CFRs during the entire study period were 1.1% (1016) for patients with CLD without cirrhosis and 6.3% (1732) with cirrhosis. Observed 30-day CFRs by month of infection varied throughout the pandemic and showed a sustained downward trend since 2022. Compared with infection in Quarter 2 of 2020 (at the beginning of the pandemic), the adjusted hazards of death at 30 days for infection in Quarter 3 of 2023 were 0.20 (95% confidence interval [CI], 0.08-0.50) for patients with CLD without cirrhosis and 0.35 (95% CI, 0.18-0.69) for patients with CLD with cirrhosis. CONCLUSIONS: In this N3C study, we found that the observed 30-day CFR decreased progressively for patients with CLD both with and without cirrhosis, consistent with broader trends seen in the general population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ge J, Far AT, Digitale JC, et al. Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study. Clin Gastroenterol Hepatol. 2024. PMID: 39181420. doi:10.1016/j.cgh.2024.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。